Back to search

Ireland· IE-PA-PA22698/024/001

Megace 40 mg/ml Oral Suspension

A megestrol product containing megestrol acetate, registered in Ireland by Bausch Health Ireland Limited. The same ATC class is registered in 11 of our 19 countries.

ATC L02AB01

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedMegace 40 mg/ml Oral SuspensionATCL02AB01REGISTER NO.IE-PA-PA22698/024/001PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Megestrol is registered in 11 of 19 countries.

Countries holding a registration under ATC L02AB01 (megestrol), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 7 of them publish a price we can compare per daily dose

Megestrol · ATC L02AB01

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of megestrol costs, country by country.

Normalised to the WHO defined daily dose (0.16 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Megestrol · price per daily dose (0.16 g)

USD · FX 28 Sept 2026

  • IT Italy$2.30
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
Megestrol acetate
Manufacturer
Bausch Health Ireland Limited
Country
Ireland (IE)
ATC code
L02AB01
ATC class
Megestrol
Defined daily dose
0.16 g, O
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    PA22698/024/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

152 interactions on record for megestrol.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Megestrol · interactions on record

152 records

  • 2 severe
  • 147 moderate
  • 3 minor

Most severe, free to view

  • DofetilideC01BD04severe
  • ThalidomideL04AX02severe
  • AprepitantA04AD12moderate
  • LiraglutidA08AX02moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Megestrol in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All megestrol products

Authorised across Europe · EMA

The same active substance is authorised in 21 EEA countries. Names it is sold under:

  • Belgium · Megace
  • Cyprus · Megace
  • Czechia · Megace, Megaplex
  • Germany · Megestat
  • Spain · Borea, Maygace Altas Dosis
  • France · Megace
  • United Kingdom (Northern Ireland) · Megace
  • Greece · Megace
  • Croatia · Megace, Megostat
  • Hungary · Cachexi, Megace
  • Italy · Gestroltex, Megace
  • Lithuania · Megace
  • Luxembourg · Megace
  • Netherlands · Megestrolacetaat Focus
  • Norway · Megace
  • Poland · Cachexan, Megace
  • Portugal · Megace, Megestrol Generis
  • Romania · Megesin
  • Sweden · Megace
  • Slovenia · Megace
  • Slovakia · Megesin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/acbc5d1a-b5b9-4f1a-95b4-c2ed44339c83
GET /v1/drugs/acbc5d1a-b5b9-4f1a-95b4-c2ed44339c83?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oral suspension",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "L02AB",
    "L02AB01"
  ],
  "strength": null,
  "pa_number": "PA22698/024/001",
  "substances": [
    "Megestrol acetate"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Marketed",
  "authorised_at": "10/12/1998",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about megestrol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.